REPORT: TPG Capital shops drug maker Aptalis, finds no takers
This article was originally published in Scrip
Private equity firm TPG Capital is shopping its specialty drug company Aptalis Pharma, asking for more than $3 billion, but the price is too rich for some potential buyers, according to Reuters.
You may also be interested in...
Using Baxter’s Advate drug as a preventative therapy helped significantly reduce bleeding incidents in a yearlong study.
Mylan CEO Heather Bresch said she is looking to do a sizable deal that helps the US generic and specialty drug maker better compete in a consolidating field of rivals.
Biogen Idec CEO George Scangos is frank about his ambitions to dominate the market for hemophilia therapies, an opportunity he compares to the big biotech’s lead treating multiple sclerosis.